Capricor Therapeutics 2026 BD opportunity scan: deramiocel and exosome pipeline, Nippon Shinyaku deal precedents, financial signals, IP risk and outreach priorities.

A focused 2026 clinical landscape deep dive into ChiCTR2600128129, evaluating SC-101 in Neoplasm Metastasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Cardurion Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07703228, evaluating Anlotinib Dihydrochloride in Non-small cell lung cancer stage IIIA: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07701512, evaluating Febuxostat in Intracranial Hemorrhages: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

CAMP4 Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Korro Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

PepGen 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into ChiCTR2600128105, evaluating Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into JPRN-UMIN000062223, evaluating On-screen Gaze Feedback in Perceptual Disorders: design, endpoints, sponsor context, readout timing and white space.

A focused 2026 clinical landscape deep dive into NCT07700875, evaluating QR-12000 in essential hypertension: design, endpoints, sponsor context, readout timing and white space.

Entrada Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.